SOUTH
SAN FRANCISCO, Calif., Jan. 5, 2024
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq:
RIGL) today announced that it has granted awards pursuant to
Rigel's Inducement Plan, approved by the Compensation Committee of
Rigel's Board of Directors and granted as an inducement material to
employees' entering into employment with Rigel, in accordance with
NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 377,900
stock options to four non-executive employees vesting over four
years with a one-year cliff.
Rigel is providing this information in accordance with NASDAQ
Listing Rule 5635(c)(4).
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
is a biotechnology company dedicated to discovering, developing and
providing novel therapies that significantly improve the lives of
patients with hematologic disorders and cancer. Founded in 1996,
Rigel is based in South San Francisco,
California. For more information on Rigel, the Company's
marketed products and pipeline of potential products,
visit www.rigel.com.
Investors & Media Contacts
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 212.600.1902
Email: david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302027467.html
SOURCE Rigel Pharmaceuticals, Inc.